Compass Therapeutics (CMPX) Equity Average (2023 - 2025)
Compass Therapeutics (CMPX) has disclosed Equity Average for 3 consecutive years, with $203.2 million as the latest value for Q4 2025.
- Quarterly Equity Average rose 54.16% to $203.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $203.2 million through Dec 2025, up 54.16% year-over-year, with the annual reading at $161.0 million for FY2025, 17.63% up from the prior year.
- Equity Average hit $203.2 million in Q4 2025 for Compass Therapeutics, up from $151.4 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $203.2 million in Q4 2025 to a low of $101.7 million in Q2 2025.
- Historically, Equity Average has averaged $149.3 million across 3 years, with a median of $151.6 million in 2024.
- Biggest YoY gain for Equity Average was 54.16% in 2025; the steepest drop was 32.88% in 2025.
- Year by year, Equity Average stood at $154.3 million in 2023, then dropped by 14.57% to $131.8 million in 2024, then surged by 54.16% to $203.2 million in 2025.
- Business Quant data shows Equity Average for CMPX at $203.2 million in Q4 2025, $151.4 million in Q3 2025, and $101.7 million in Q2 2025.